Skip to main content

Peer Review reports

From: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

Original Submission
29 Oct 2015 Submitted Original manuscript
12 Nov 2015 Reviewed Reviewer Report - Roberto Passera
30 Nov 2015 Reviewed Reviewer Report - Line Tarpgaard
17 Dec 2015 Author responded Author comments - Antoine Adenis
Resubmission - Version 2
17 Dec 2015 Submitted Manuscript version 2
26 Dec 2015 Reviewed Reviewer Report - Hidekazu Kuramochi
15 Jan 2016 Author responded Author comments - Antoine Adenis
Resubmission - Version 3
15 Jan 2016 Submitted Manuscript version 3
26 Feb 2016 Author responded Author comments - Antoine Adenis
Resubmission - Version 4
26 Feb 2016 Submitted Manuscript version 4
18 Apr 2016 Author responded Author comments - Antoine Adenis
Resubmission - Version 5
18 Apr 2016 Submitted Manuscript version 5
18 May 2016 Author responded Author comments - Antoine Adenis
Resubmission - Version 6
18 May 2016 Submitted Manuscript version 6
Publishing
22 Jun 2016 Editorially accepted
7 Jul 2016 Article published 10.1186/s12885-016-2440-9

You can find further information about peer review here.

Back to article page